On August 3, 2020 20/20 GeneSystems, reported that in partnership with Linkou Chang Gung Memorial Hospital, the largest hospital in Taiwan, it has won the 2020 Taipei Biotech "Technology Transfer Cooperation Award" Gold Medal Award, the Oscar in the biotechnology industry, for its OneTest an artificial intelligence (AI) powered blood test that can assist in the early detection of many common cancers (Press release, 20/20 GeneSystems, AUG 3, 2020, View Source [SID1234562725]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Linkou Chang Gung Memorial Hospital, a multi-specialty hospital recognized as a powerhouse and pioneer in innovation, research and teaching, used its technology transfer rights to exclusively authorize 20/20 GeneSystems "Multiple Cancer Screening with Tumor Markers and Machine Learning Algorithms" technology platform to qualify.
The technology has been patented in Taiwan and the United States. Through the combination of tumor markers, machine learning and physician interpretation, OneTest can screen for multiple cancers at one time. The screening process provides no radiation exposure but rather low invasive detection, reducing the psychological pressure of the tested patients, and making the interpretation of test results more objective through blood sampling data and AI-assisted analysis.
"We are so proud to partner with Linkou Chang Gung Memorial Hospital and win the Gold Medal Taipei Biotech Award. The OneTest is based on innovative technology that drives cancer screening with AI technology, which is helpful for early cancer screening and early intervention treatment to improve patient survival rate," said founder of 20/20 GeneSystems, Jonathan Cohen. "The award properly reflects the great value OneTest brings to the hundreds of millions of people who routinely receive tumor markers screenings as part of their annual physical exam packages in eastern Asia, especially in China."
"This adds to the list of major achievements we have made in part 6 months, including the publication of a peer-reviewed research article in a prestigious scientific journal, and the admission to and graduation from the highly selective Ping An Accelerator," said Dr. Jiming Zhou, the head of 20/20’s eastern Asia operations.
20/20 GeneSystems has its roots in machine learning as a result of the work it has done over the years to develop OneTest. In the U.S., OneTest has been used by firefighters and departments across the U.S. to help combat firefighting related cancers.
Since late March, 20/20 has been importing and distributing in the U.S. rapid COVID-19 antibody tests and will continue to work with the manufacturers of those tests to help them obtain EUAs for their use at the point of care in accordance with the latest Guidance from the FDA.